Search clinical trials for: Extended Release Opioid Formulation, Shortened Intervals

Total 120 results

Friends Research Institute, Inc.

Not yet recruiting

Buprenorphine for Individuals in Jail

Opioid Use Disorder

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Suspended

Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder

Opioid-use Disorder

United States
Yale University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Alcohol Pharmacotherapy for HIV+ Prisoners (INSPIRE)

Alcohol Dependence | Human Immunodeficiency Virus | AIDS | Hazardous Drinking | Problem Drinking

United States
Wake Forest University
EKR Therapeutics, Inc

Terminated

Low Dose Extended-release Epidural and Lumbar Plexus Block Compared to Lumbar Plexus Block for Total Hip Resurfacing

Hip Arthroplasty

United States
Shaare Zedek Medical Center

Unknown

Safety and Effectiveness of Tramadex-OD After Knee Arthroscopy

Postoperative Pain

Israel
AbbVie (prior sponsor, Abbott)

Completed

Hydrocodone/Acetaminophen for Acute Pain Following Bunionectomy

Pain

United States
Abbott

Completed

A Study Comparing the Analgesic Efficacy and Safety of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR)and Placebo in Subjects With Osteoarthritis

Pain
Endo Pharmaceuticals

Suspended

Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced Children

Chronic Pain | Postsurgical Pain

United States
NYU Langone Health
National Institute on Drug Abuse (NIDA)

Not yet recruiting

Assessing Optimal XRB Initiation Points in Jail

Opioid Use Disorder

United States
Cephalon

Completed

A Study to Evaluate the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Hepatic Function and Subjects With Moderate Hepatic Impairment

Hepatic Impairment

United States
Indivior Inc.

Completed

SUBLOCADE Rapid Initiation Study

Opioid-use Disorder

United States
Duke University

Completed

Effect of Bupropion on Seizure Threshold in Depressed Patients

MDD

United States
University of Texas Southwestern Medical Center
National Institute on Drug Abuse (NIDA)

Recruiting

Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2) (CURB-2)

Cocaine Use Disorder

United States
University of Rochester
Endo Pharmaceuticals

Terminated

Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis

Multiple Sclerosis | Chronic Pain | Neuropathic Pain

United States
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Terminated

A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

Diabetic Neuropathy, Painful | Diabetic Polyneuropathy

United States
Shire

Completed

Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476

Colitis, Ulcerative

Belgium
Ensysce Biosciences
PRA Health Sciences

Completed

Study of PF614 Compared to OxyContin® in Healthy Volunteers (SAD)

Healthy

United States
University of Louisville
EKR Therapeutics, Inc

Terminated

Combination of Peripheral Nerve Block and DepoDur in Total Knee Joint Replacement

Arthroplasty, Replacement, Knee

United States
Friends Research Institute, Inc.
National Institute on Drug Abuse (NIDA)

Completed

Extended Release Naltrexone for Opioid-Dependent Youth

Drug Dependence

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time

Chronic Pain

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain

Low Back Pain

United States
EKR Therapeutics, Inc
Pacira Pharmaceuticals, Inc

Completed

A Pharmacokinetic (PK) Study of Extended-Release Epidural Morphine in Upper Abdominal Surgery

Postoperative Pain
Shire

Completed

Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

Belgium
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time

Chronic Pain

United States
Pfizer

Completed

Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain

Chronic Noncancer Pain

United States
Hospital Central Dr. Luis Ortega

Completed

Oxycodone Extended-release in the Treatment of Perioperative Pain in Patients Undergoing Orthopaedic Surgery

Surgery

Venezuela
Stanford University

Completed

Effects of Epidural Lidocaine on the Pharmacokinetic and Pharmacodynamic Profiles of DepoDur® After Cesarean Delivery

Epidural Analgesia, Obstetric

United States
Cephalon

Completed

A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users

Drug Abuse

United States, Canada
Torrent Pharmaceuticals Limited

Completed

Bioequivalence Study of Torrent Pharmaceutical Limited's Venlafaxine Hydrochloride ER Capsules Under Fed Conditions

Healthy
Cephalon

Completed

A Study to Assess the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Renal Function and Subjects With Varying Degrees of Renal Impairment

Renal Impairment

United States
NYU Langone Health
NYC Health + Hospitals

Completed

XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept

Opioid Dependence

United States
Pfizer

Completed

A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee

Osteoarthritis | Chronic Pain

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets

Low Back Pain

United States
Yih-Ing Hser
National Institute on Drug Abuse (NIDA); University of California, Los Angeles and other collaborators

Not yet recruiting

Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR) (RXR)

Substance-Related Disorders | Opioid-Related Disorders | Narcotic-Related Disorders

United States
Wake Forest University Health Sciences

Withdrawn

Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films

Opioid Use
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy

Diabetic Peripheral Neuropathy

United States, Canada, Puerto Rico
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain

Pain | Osteoarthritis | Low Back Pain

United States, Australia, Canada, New Zealand
Centre Hospitalier Universitaire de Tivoli

Completed

Sufentanil Sublingual Tablet System for Postoperative Pain Management After Total Knee Arthroplasty

Postoperative Pain

Belgium
NYU Langone Health
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Completed

Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment

Opioid Use Disorder

United States
Janssen Scientific Affairs, LLC

Withdrawn

An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)

Pain | Chronic Low Back Pain | Chronic Back Pain | Osteoarthritis Pain In The Hip or Knee

United States
Grünenthal GmbH
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine

Pain | Tumor

Austria, Bulgaria, Croatia, Czechia, France, Germany, Hungary, Italy, Moldova, Republic of, Poland, Romania, Russian Federation, Serbia, Slovakia, Spain, Sweden
Pacira Pharmaceuticals, Inc
Registrat-Mapi

Terminated

A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B301 (IMPROVE-Open)

Bowel Obstruction

United States
University of California, Los Angeles
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Completed

Cocaine Use Reduction With Buprenorphine (CURB)

Cocaine Dependence

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pivotal Study to Evaluate the Bio-equivalence of the Tapentadol Extended-Release (ER) Tamper-resistant Formulation (TRF) Tablet to the Current Tapentadol ER Prolonged-release 2 (PR2) Tablet

Healthy

United States
Ensysce Biosciences
PRA Health Sciences

Completed

Evaluation of Oral PF614 Relative to OxyContin

Healthy Volunteers

United States
Paolo Mannelli
Alkermes, Inc.

Completed

Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence (BUP/NXT-VIVI)

Opiate Dependence

United States
University of Oslo
Norwegian Institute of Public Health; Oslo University Hospital; The Research... and other collaborators

Completed

Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway (NTX-SBX)

Opioid Dependence

Norway
Pfizer

Completed

Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)

Healthy

Canada
Lyndra Inc.
National Institute on Drug Abuse (NIDA)

Withdrawn

Study of LYN-014 in Individuals With Opioid Use Disorder Who Are Stable on Methadone Therapy

Opioid Use Disorder, Moderate
Rhode Island Hospital

Recruiting

Combined Injectable Treatment for HIV and OUD (CHOICE)

Opioid Use Disorder | Human Immunodeficiency Virus

United States

3

Subscribe